Compounds > n-acetylgalactosaminuronic acid
Page last updated: 2024-12-08

n-acetylgalactosaminuronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetylgalactosaminuronic acid: epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A & H [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID134107
SCHEMBL ID7156151
MeSH IDM0180822

Synonyms (11)

Synonym
galnaca
2-(acetylamino)-2-deoxy-l-galacturonic acid
2-n-acetyl-2-deoxygalacturonic acid
2-n-acetyl-2-deoxy-l-galacturonic acid
2-nadga
n-acetylgalactosaminuronic acid
82838-35-5
l-galacturonic acid, 2-(acetylamino)-2-deoxy-
(2r,3s,4s,5s)-5-acetamido-2,3,4-trihydroxy-6-oxohexanoic acid
SCHEMBL7156151
2-acetamido-2-deoxy-l-galacturonic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (40.00)18.2507
2000's2 (20.00)29.6817
2010's3 (30.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uridine diphosphate n-acetylglucosamine
Uridine Diphosphate N-Acetylglucosamine: Serves as the biological precursor of insect chitin, of muramic acid in bacterial cell walls, and of sialic acids in mammalian glycoproteins.		2.0810
galactosamine
2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.		2.0810D-galactosamine;
primary amino compound		toxin
acetylgalactosamine
Acetylgalactosamine: The N-acetyl derivative of galactosamine.		1.9710N-acetyl-D-hexosamine;
N-acetylgalactosamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		1.9710D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
udp-n-acetylglucosaminuronic acid
UDP-N-acetylglucosaminuronic acid: found in Micrococcus luteus		2.0210
lipid a
Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).		2.1310dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite
leptin
Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		02.2510
Diabetes Mellitus, Adult-Onset
[description not available]		02.0210
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.0210
Insulin Sensitivity
[description not available]		02.0210
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		02.0210
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0210
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		02.0210
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.0210
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.0410
Infections, Pseudomonas
[description not available]		01.9710
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		01.9710